Leafly Holdings, Inc. (NASDAQ:LFLY), a leading online cannabis discovery marketplace and resource for cannabis consumers, today announced a new program that allows accredited cannabis researchers to supplement their work with a large cannabis dataset that would otherwise not be available.
Novartis Presents New Long-Term Leqvio Data Demonstrating Consistent Efficacy And Safety Beyond Six Years
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-–C) reduction beyond six years of treatment1
Eight in ten patients achieved target LDL-C threshold**, in line with previously reported Phase III data1-3
